Walid M. Awni,Barry M. Bernstein,Andrew L. Campbell,Sandeep Dutta,Chih-Wei Lin,Wei Liu,Tami Pilot-Matias,Rajeev M. Menon,Sven Mensing,Thomas J. Podsadecki,Lino Rodrigues Junior,Suvajit Samanti,Roger T
申请号：
US15782162
公开号：
US20180042982A1
申请日:
2017.10.12
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention generally features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16, 12 or 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. Further, additional compounds such as sofosbuvir, or its pharmaceutically acceptable salt may be used for retreatment of HCV patients who have failed glecaprevir and pibrentasvir combination therapy.
